Efficacy and safety of pegylated-interferon alpha therapy in patients with chronic hepatitis B in recource-limited settings: A Serbian single-center experience

Ksenija Bojović; Jelena  Jordović; Jasmina Simonović Babić; Dragan Delić; Nikola Mitrović; Nataša Katanić

doi:10.2298/VSP180727150B

Ksenija Bojović University of Belgrade, Faculty of Medicine, Belgrade, Serbia
Jelena Jordović University of Belgrade, Faculty of Medicine, Belgrade, Serbia
Jasmina Simonović Babić University of Belgrade, Faculty of Medicine, Belgrade, Serbia
Dragan Delić University of Belgrade, Faculty of Medicine, Belgrade, Serbia
Nikola Mitrović University of Belgrade, Faculty of Medicine, Belgrade, Serbia
Nataša Katanić University of Belgrade, Faculty of Medicine, Belgrade, Serbia

DOI: https://doi.org/10.2298/VSP180727150B

Keywords: biochemistry, hepatitis b, antigens, hepatitis b, chronic, peginterferon alfa-2, treatment outcome, virology

Abstract

Background/Aim. In Serbia, pegylated interferon (PEG-IFN) alpha-2a has been registered since 2013 for the treatment of patients with chronic hepatitis B (CHB). Numerous advantages, new experiences during the past five years and lack of any published data in our specific population, have initiated this study, with the aim to examine efficacy and safety of PEG-IFN in patients in a Serbian referral center. Methods. This prospective study included 36 patients with CHB who were treated in the Hepatology Department of the Clinic for Infectious and Tropical Diseases, Clinical Center of Serbia in Belgrade, during 2012–2017. Patients had a standard 48-week treatment protocol with PEG-IFN, with measurements of liver enzymes, serology and viraemia before, during, at the end of the treatment and follow-up 6 months afterwards. Treatment outcome was determined using serology (clearance of HBeAg), biochemical [normalization of alanine aminotransferase (ALT)] and virological response [hepatitis B virus (HBV) DNA < 2,000 IU/mL]. Results. Virological success in patients with HBeAg positive CHB was achieved in 50% of patients, HBeAg clearance in 62.5%, and normalization of ALT in 37.5% of patients. In patients with HBeAg negative CHB, 38% of the patients achieved virologic success, biochemical success was obtained in 47.6% of the patients and only one (4.7%) patient had HBsAg clearance. Conclusion. PEG-IFN is important for treatment of patients with CHB in well-defined situations, and in our population success rates are similar to other published studies. Although safety and tolerability are satisfactory, there is a possibility of more serious side-effects so it is necessary to monitor patients regularly during the treatment.

References

European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57(1): 167–85.

European Association for the Study of the Liver. EASL 2017 Clini-cal Practice Guidelines on the management of hepatitis B vi-rus infection. J Hepatol 2017; 67(2): 370–98.

Health Insurance Fund of the Republic of Serbia. List C. Drugs with a special regime of release. [Cited 2018 May 30] Available from: https://www.rfzo.rs/download/pravilnici/lekovi/Lista %20Cprimena%20od%2001.01.2018..pdf

Sonnevald MJ, Hansen BE, Piratvisuth T, Jia J, Zeuzem S, Gane E, et al. Response guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen level. Hepatology 2013; 58(3): 872–80.

Chon YE, Kim DJ, Kim SG, Kim HG, Bae SH, Hwang SG, et al. An observational, muticenter, cohort study evaluating the an-tiviral efficacy and safety in korean patients with chronic hep-atitis B receiving pegylated interferon-alfa 2a (Pegasys). Medi-cine 2016; 95(14): e3026.

Vlachogiannakos J, Papatheodoridis GV. Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients? Liver Int 2015; 35(Suppl 1): 100–6.

Lampertico P, Rothe V, Caputo A, Papatheodoridis GV. A base-line predictive tool for selecting HBeAg-negative chronic hep-atitis B patients who have a high probability of achieving sus-tained immune control with peginterferon alfa-2a. Hepatology 2014; 60: 1107A.

Goulis I, Karatapanis S, Akriviadis E, Deutsch M, Dalekos GN, Raptopoulou-Gigi M, et al. On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients. Liver Int 2015; 35(5): 1540–8.

Milosevic I, Delic D, Lazarevic I, Pavlovic IP, Korac M, Bojovic K, Jevtovic D. The significance of hepatitis B virus (HBV) geno-types for the disease and treatment outcome among patients with chronic hepatitis B in Serbia. J Clin Virol 2013; 58(1): 54–8.

Bojović K, Božić M, Stanojević B, Popović N. The first resultsof genotyping hepatitis B virus in Serbia and Montenegro, Falk symposium 157 Chronic Hepatitis: metabolic, Cholestatic, Vi-ral and Autoimmune. Freibug; 2006. Abstracts 21.

Lampertico P, Maini M, Papatheodoridis G. Optimal management of hepatitis B virus infection - EASL Special Conference. J Hepatol 2015; 63(5): 1238–53.

Marcellin P, Bonino F, Yurdaydin C, Hadziyannis S, Moucari R, Kapprell HP, et al. Hepatitis B surface antigen levels: associa-tion with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. Hepatol Int 2013; 7(1): 88–97.

Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, et al. Sustained HBeAg and HBsAg loss after long-term fol-low-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135(2): 459–67.

Piratvisuth T, Marcellin P, Brunetto M, Bonino F, Farci P, Yurday-din C, et al. Sustained immune control 1 year post-treatment with Peginterferon Alfa -2a [40KD] (PEGASYS) is durable up to 5 years post-teratment and is associated with a hihg rate of HBsAg clearance in HbeAg-negative chronic hepatitis B. 20th Conference of the Asian Pacific Asspciation for the Study of the Liver (APASL); Bejing, China 2010 March 25–28.

Vigano M, Invernizzi F, Lampertico P. Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative pa-tients? Liver Int 2015; 35(Suppl 1): 107–13.

Yeh ML, Peng CY, Dai CY, Lai HC, Huang CF, Hsieh MY, et al. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients. PLoS One 2015; 10(4): e0122259.

Rijckborst V, Hansen BE, Ferenci P, Brunetto MR, Tabak F, Cakaloglu Y, et al. Validation of a stopping rule at week 12 us-ing HBsAg and HBV DNA for HBeAg-negative patients treat-ed with peginterferon alfa-2a. J Hepatol 2012; 56(5): 1006–11.

Lampertico P, Viganò M, Di Costanzo GG, Sagnelli E, Fasano M, Di Marco V, et al. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut 2013; 62(2): 290–8.